ON-DEMAND WEBINAR
Intended for US Healthcare Professionals Only.
ON-DEMAND WEBINAR
Presented By:
Ellis J. Neufeld, MD, PhD
Clinical Director and Executive Vice President
John and Lorine Thrasher Endowed Chair
St. Jude Children's Research Hospital
Dr. Neufeld will share final results from the landmark NuProtect study—the largest prospective clinical trial with a single FVIII product in previously untreated patients (PUPs) with hemophilia A completed to date. The completion of this study is a major milestone for NUWIQ and the hemophilia community.
Barbara A. Konkle, MD
Associate Chief Scientific Officer and Director
Hemostasis, Platelet Immunology & Genomics Laboratory, Bloodworks Northwest
Professor of Medicine/Hematology, University of Washington
Dr. Konkle will contextually discuss 8CHECK, a free F8 gene mutation testing service offered by Octapharma, developed to inform and improve treatment decisions in hemophilia A.
Octapharma’s commitment to patient care started at the very beginning. Founded in 1983 on the principle of enhancing the lives of patients across the world, Octapharma is focused exclusively on the development and manufacturing of high-quality human proteins to meet the unmet clinical needs of patients, especially those with rare conditions, in hematology, immunotherapy and critical care.
Indications and Important Safety Information for NUWIQ® [Antihemophilic Factor (Recombinant)].
Please see NUWIQ full Prescribing Information. Instructions For Use
Indications and Usage
NUWIQ® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ® is not indicated for the treatment of von Willebrand Disease.
Contraindications
NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.
Warnings and Precautions
Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.
The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).
Adverse Reactions
The most frequently occurring adverse reactions (>5%) in clinical trials were upper respiratory tract infection, headache, fever, cough, lower respiratory tract infection, rhinitis, chills, abdominal pain, arthralgia, anemia, and pharyngitis.
Please see NUWIQ full Prescribing Information. Instructions For Use
|